Patient, relative and staff experiences of clinical trial participation in neurooncology

• Verfasst von: Thallner, Ronja [VerfasserIn]
• Verfasst von: Gumbinger, Christoph [VerfasserIn]
• Verfasst von: Hohmann, Anja [VerfasserIn]
• Verfasst von: Wick, Antje [VerfasserIn]
• Verfasst von: Wick, Wolfgang [VerfasserIn]
• Verfasst von: Busetto, Loraine [VerfasserIn]
• Titel: Patient, relative and staff experiences of clinical trial participation in neurooncology
• Titelzusatz: "Maybe you can also show the positive, no matter how it ends"
• Verf.angabe: Ronja Thallner, Christoph Gumbinger, Anja Hohmann, Antje Wick, Wolfgang Wick, Loraine Busetto
• E-Jahr: 2024
• Jahr: 21 June 2024
• Umfang: 14 S.
• Fussnoten: Gesehen am 10.12.2024
• Titel Quelle: Enthalten in: Cancer management and research
• Ort Quelle: Albany, Auckland : Dove Medical Press, 2009
• Jahr Quelle: 2024
• Band/Heft Quelle: 16(2024), Seite 663-676
• ISSN Quelle: 1179-1322
• DOI: doi:10.2147/CMAR.S447407
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1911766503

Abstract

Purpose: There is a lack of evidence regarding how patients with malignant brain tumor and their relatives experience participation in neurooncological clinical trials. Similarly, insights from the perspective of trial staff caring for this group of patients are missing. This study aims to investigate patient, relative and trial staff experiences regarding participation in clinical neurooncological trials. Methods: Within a qualitative exploratory study, 29 semi-structured interviews with brain tumor patients, relatives and trial staff were conducted and analyzed using reflexive thematic analysis (RTA) by Braun and Clarke. A patient researcher and patient council were involved in data analysis and interpretation. Results: Four themes were developed reflecting significant aspects of the trial experience: 1. “It all revolves around hope”; 2. “Trial participation: experiencing unique medical care”; 3. “Everyone’s roles are changing”; 4. “Communication as a possible area of conflict”. Experiencing trial participation and general medical treatment were found to be interconnected to such a degree that they were often not meaningfully distinguished by patients and relatives. Conclusion: In addition to assessing traditional endpoints for patient outcomes, we recommend increased emphasis on investigating the impact of the “soft” components constituting trial participation. Due to the interconnectedness of medical treatment and trial participation, we recommend further investigation in comparison to experiences in regular care. A deeper understanding of trial participation is needed to inform improvements for patient experiences and staff satisfaction alongside medical and scientific progress.